Affimed Appoints New CEO, Shares Fall on Leadership Change

Company Overview - Affimed N.V. has appointed Shawn M. Leland as the new CEO, replacing Andreas Harstrick, who will remain as the chief medical officer [1] - Following the announcement, shares of Affimed declined by 6.6% on September 3 [1] Stock Performance - Year-to-date, Affimed's shares have decreased by 36.8%, while the industry has seen a slight increase of 0.6% [2] Pipeline Development - Affimed's clinical-stage pipeline includes three investigational candidates: AFM24, acimtamig (AFM13), and AFM28, which are being developed for various oncology indications [2] - The AFM24-102 study is assessing AFM24 in combination with Roche's Tecentriq for refractory non-small cell lung cancer [3] - The LuminICE-203 study is evaluating acimtamig in combination with AlloNK cells for refractory Hodgkin's Lymphoma [3] - AFM28 is being evaluated as a monotherapy in a phase I dose-escalation study for refractory acute myeloid leukemia [4] Revenue Generation - Affimed currently generates revenue from a platform license provided to Genentech, a subsidiary of Roche [2] Future Outlook - The successful development of pipeline candidates is crucial for Affimed, as it currently lacks a marketed product [4] - The impact of the new CEO on the company's ongoing business operations and pipeline development remains to be seen [4]